What future for Teva Oncology?

Quote

anonymous

Guest
  1. Specialty: Bendeka and Trisenox are dying a slow death as the patents run out, with Teva spending $0 on new trials, label expansions, etc.
  2. Biosimilars: we’re supposedly in this game, but the past two years Teva has spent peanuts on pre-launch and education, as opposed to the mega presence of Amgen, Genentech, Pfizer, etc, in Biosimilars.

What will reps do a year from now.? They should have just sold off the business unit a year ago like they were threatening to.
 




As a Teva Oncology escapee, wake up, all of you need to get out! Holding on for minor financial incentives to stay is a mistake, unless you are planning to retire. Teva Oncology is dead and the sales people who stay lack real recruit-ability. You are viewed as poor candidates for remaining part of a dying business unit.
 




anonymous said:
Teva ONC reps already has dibs on internal positions. We all have opportunities to stay, which I'll be doing.
Click to expand...

“Dibs”. Seriously? Who uses that expression? Are you competing to ride in the front seat of a car with your friends? You proved the point on recruit-ability. Your intelligence is a reflection of your statement above.
 

























Write your reply...
Top Bottom
Back
Quote